Table II:
Chronic Graft-versus-Host Disease Characteristics
| All Patients N (%) or median (IQR) | |
|---|---|
| All | 204 |
| Transplant to Consent (months) | 36.2 (21.9–62.6) |
| Transplant to cGVHD Diagnosis (months) | 6.9 (4.6–12.0) |
| cGVHD Diagnosis to Consent (months) | 26.1 (12.5–54.7) |
| cGVHD Organ Involvement | |
| Eyes | 152 (75) |
| Gastrointestinal Tract | 95 (47) |
| Joints and Fascia | 122 (60) |
| Liver | 91 (45) |
| Lungs | 145 (71) |
| Mouth | 134 (66) |
| Skin | 159 (78) |
| Genital (female patients only) | 46 (55) |
| Number of Organs Affected by cGVHD | |
| 1–2 | 13 (6) |
| 3–4 | 62 (30) |
| 5–6 | 73 (36) |
| 7–8 | 56 (27) |
| Average NIH Organ Score | 1.00 (0.71–1.38) |
| NIH Global Score | |
| Mild | 4 (2) |
| Moderate | 60 (29) |
| Severe | 140 (69) |
| Prior Acute GVHD | |
| No | 65 (32) |
| Yes | 138 (68) |
| Unknown | 1 (<1) |
| Number of Prior cGVHD Systemic Treatment Regiments | |
| <2 | 14 (7) |
| 2–3 | 69 (34) |
| 4–5 | 70 (34) |
| >5 | 50 (25) |
| Unknown | 1 (<1) |
| Ever Treatment with cGVHD Systemic Treatments | |
| Steroid | 189 (93) |
| CNI | 173 (85) |
| Sirolimus | 70 (34) |
| MMF | 100 (49) |
| ECP/PUVA | 88 (43) |
| Rituximab | 51 (25) |
| Intensity of Immunosuppression at Evaluation | |
| None/Mild | 49 (24) |
| Moderate | 70 (34) |
| High | 84 (41) |
| Unknown | 1 (<1) |
Abbreviations: CNI–calcineurin inhibitor; MMF–mycophenolate mofetil; ECP–extracorporeal photopheresis; PUVA–psoralen and ultraviolet A therapy.
Intensity of current immunosuppression is defined as mild (single-agent prednisone 0.5 mg/kg/d), moderate (single-agent prednisone 0.5 mg/kg/d and/or any single agent/modality), high (2 or more agents/modalities +/− prednisone 0.5 mg/kg/d)27